A Prospective, Open-Label, Randomized, Active Control, Parallel Group, Comparative, Multi-Center, Phase IV Trial to Evaluate the Immunogenicity of Wockhardt's Insulin analogue Glargine (Glaritus) with Sanofi-Aventis Insulin analogue Glargine (Lantus) in Subjects with Type 2 Diabetes Mellitus

Trial Profile

A Prospective, Open-Label, Randomized, Active Control, Parallel Group, Comparative, Multi-Center, Phase IV Trial to Evaluate the Immunogenicity of Wockhardt's Insulin analogue Glargine (Glaritus) with Sanofi-Aventis Insulin analogue Glargine (Lantus) in Subjects with Type 2 Diabetes Mellitus

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Wockhardt
  • Most Recent Events

    • 30 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top